We are pleased to announce our medicinal cannabis cultivation and manufacturing facility has received the required licences and permits from the Office of Drug Control (ODC) and the Good Manufacturing Practise (GMP) licence from the Therapeutic Goods Administration (TGA).
We are now well-positioned to meet growing market demands for medicinal cannabis in Australia and overseas – this is an exciting development for ANTG’s position in helping to shape not only the future of Australia’s medicinal cannabis industry, but also the global industry. Exportation will begin to Germany, where we have signed a 10-year supply contract with Cannamedical Pharma GmbH. Cannamedical is a leading independent medical cannabis wholesaler, distributing medicinal cannabis throughout Germany and the European Union. In the first 12 months we expect to see two tonnes plus in export. Read our CEO, Matt Cantelo’s, interview with the Financial Review to learn more about exportation plans, supplying the Australian market and expectations for the future.
Multiple licences and permits are required when manufacturing medicinal cannabis in Australia as well as exporting medicinal cannabis overseas. These requirements include ARTG registration, licences and permits issued by the Office of Drug Control (ODC) and Drug Control Section (DCS), the Therapeutic Goods Administration (TGA), as well as the state. Each individual requirement plays a crucial role in ensuring the manufacturing and quality of medicinal cannabis meet the standards set by Australia, and standards set overseas.
The Office of Drug Control regulates and provides advice on the import, export and manufacture of controlled drugs, as well as the cultivation of cannabis for medicinal purposes to support Australia’s obligations under International Drug Conventions.
The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for therapeutic goods, carrying out a range of assessment and monitoring activities to ensure access to therapeutic goods formulated and manufactured in Australia are of good quality and meets the regulatory standards for therapeutic goods.
Good manufacturing practice (GMP) describes the minimum standard that a medicines manufacturer must meet in their production processes. The European Medicines Agency (EMA) coordinates inspections to verify compliance with these standards and plays a key role in harmonising GMP activities at European Union (EU) level. Any manufacturer of medicines intended for the EU market, no matter where in the world it is located, must comply with GMP.
With future market expansion and early-market entry in mind, we are proud to announce our facility meets both Australian and European regulations for processing medicinal cannabis, including future exportation of pharmaceutical grade products. Thanks to our superior cultivation processes and our passionate and driven team of experts, we are confident that the future of ANTG and our impact on the medicinal cannabis industry looks bright.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >